Accumulating evidence indicates a specific role for IFN-β, even when administered at a low dose, in counteracting CSC stemness in breast cancer, not only through immunomodulating mechanisms, but also by transcriptionally controlling CSC differentiation [40,42]. The gene discussed is IFNB1; the disease is breast cancer.